May. 22 at 2:10 PM
🚨
$CUE Entering a New Growth Phase With Major 2026 Catalysts
Cue Biopharma is developing targeted immune therapies designed to selectively activate the body’s immune system for cancer.
Cue Biopharma continues stacking catalysts in 2026:
🔹 Presenting at the Jefferies Global Healthcare Conference on June 3rd, giving CUE major exposure to institutional healthcare investors.
🔹 Expanded pipeline with Ascendant-221, a clinical stage anti-IgE antibody targeting allergic diseases and expanding CUE into large immunology markets.
🔹 Company also secured a
$30M private placement to strengthen the balance sheet and support pipeline expansion.
🔹 Received a
$7.5M milestone payment from Boehringer Ingelheim.
With oncology and allergy/immunology markets representing multi billion dollar opportunities globally, CUE is positioning itself in some of the largest and fastest-growing areas in biotech.
Communicated Disclaimer: https://stockresearchtoday.com/cue/
Sector peers:
$MRNA
$BNTX
$NKTX
$IMTX